MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT

NMPA APPROVAL FOR REGISTRATION APPLICATION OF ANCHORMAN® LAAC SYSTEM

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement and product development progress of the Group. Reference is made to the announcement dated January 1, 2024 in relation to, among other things, the acquisition of 51% equity interest in MP CardioAdvent (the "**Announcement**"). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The board of directors of the Company (the "**Board**") is pleased to announce that, on January 5, 2024, MP CardioAdvent received the approval from the National Medical Products Administration of the People's Republic of China (國家藥品監督管理局) ("**NMPA**") regarding the registration application for AnchorMan® left atrial appendage (the "**LAA**") closure system (the "**AnchorMan® LAAC System**"), the self-development product of MP CardioAdvent, which is also the only approved semi-closed type LAAC product in China so far. In addition, it completed the registration application of CE Mark in December 2023.

AnchorMan® LAAC System comprises a LAA closure and a delivery system, which is applicable for patients with nonvalvular atrial fibrillation with the CHA2DS2-VASC (a stroke risk assessment tool) score ≥2 and have contraindications in long-term oral anticoagulation therapy or still at risk of stroke after anticoagulation therapy.

The major innovative designs of AnchorMan® LAAC System include:

- the semi-closed structure formed by the 12 "3D folding" units and the frame combines the merits of an open and closed closure device, solving the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA, and achieving stable anchoring ;

- the rounded and soft distal end could reduce damage to the LAA tissue;

- the dense NiTi alloy frame design allows very tight conformity to the anatomy of LAA and achieves better sealing performance; and

- two deployment models of advancement and unsheathe are available to provide more options for physicians.

In addition, AnchorMan® LAAC System is available in six closure device diameters ranging from 20 mm to 35 mm for a larger patient population.

The NMPA registration approval of the AnchorMan® LAAC System enables the Group to expand its business from heart valves to a new segment in the structural heart disease field with large patient population and fast growth rate, which will further expand the Company's revenue stream and enhance its comprehensive competitiveness.

The Company cannot guarantee that AnchorMan® LAAC System will be ultimately commercialized successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, January 7, 2024

As of the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.